These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30902802)

  • 21. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):486-491. PubMed ID: 28031486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.
    Subhani S; Jamil K
    Biomed Pharmacother; 2015 Jul; 73():65-74. PubMed ID: 26211584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.
    Moore CD; Shahrokh K; Sontum SF; Cheatham TE; Yost GS
    Biochemistry; 2010 Oct; 49(41):9011-9. PubMed ID: 20812728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. beta-caryophyllene oxide and trans-nerolidol affect enzyme activity of CYP3A4 - in vitro and in silico studies.
    Špičáková A; Bazgier V; Skálová L; Otyepka M; Anzenbacher P
    Physiol Res; 2019 Nov; 68(Suppl 1):S51-S58. PubMed ID: 31755290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.
    Danielson ML; Desai PV; Mohutsky MA; Wrighton SA; Lill MA
    Eur J Med Chem; 2011 Sep; 46(9):3953-63. PubMed ID: 21703735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DR-predictor: incorporating flexible docking with specialized electronic reactivity and machine learning techniques to predict CYP-mediated sites of metabolism.
    Huang TW; Zaretzki J; Bergeron C; Bennett KP; Breneman CM
    J Chem Inf Model; 2013 Dec; 53(12):3352-66. PubMed ID: 24261543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidating substrate promiscuity in the human cytochrome 3A4.
    Hayes C; Ansbro D; Kontoyianni M
    J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.
    Sevrioukova IF; Poulos TL
    J Biol Chem; 2012 Jan; 287(5):3510-7. PubMed ID: 22157006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the active site properties of CYP4F12.
    Eksterowicz J; Rock DA; Rock BM; Wienkers LC; Foti RS
    Drug Metab Dispos; 2014 Oct; 42(10):1698-707. PubMed ID: 25074871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.
    Ekins S; Bravi G; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 1999 Oct; 291(1):424-33. PubMed ID: 10490933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
    Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Mechanism-Based Model for the Prediction of the Metabolic Sites of Steroids Mediated by Cytochrome P450 3A4.
    Dai ZR; Ai CZ; Ge GB; He YQ; Wu JJ; Wang JY; Man HZ; Jia Y; Yang L
    Int J Mol Sci; 2015 Jun; 16(7):14677-94. PubMed ID: 26133240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
    Basheer L; Schultz K; Fichman M; Kerem Z
    PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.
    Mannu J; Jenardhanan P; Mathur PP
    J Mol Model; 2011 Aug; 17(8):1847-54. PubMed ID: 21080015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay.
    Wang L; Hai Y; An L; Chen J; Liang R; He X
    Bioorg Med Chem; 2017 May; 25(10):2689-2700. PubMed ID: 28372934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling the Ligand-Binding Sites of CYP3A4 by Molecular Dynamics Simulations with Solvent Probes.
    Feng Y; Gong C; Zhu J; Liu G; Tang Y; Li W
    J Chem Inf Model; 2024 Apr; 64(8):3451-3464. PubMed ID: 38593186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
    Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.
    Shin YG; Le H; Khojasteh C; Hop CE
    Comb Chem High Throughput Screen; 2011 Nov; 14(9):811-23. PubMed ID: 21605066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.